Aripiprazole for Dermatillomania

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Chicago, Chicago, IL
Dermatillomania+2 More
Aripiprazole - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Eligible Conditions

  • Dermatillomania
  • Trichotillomania (Hair-Pulling Disorder)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Dermatillomania

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 6 weeks

6 weeks
Cambridge Caffeine Use Survey
Cambridge-Chicago Trait Scale
Clinical Global Impressions-Improvement Scale (CGI-I)
Hamilton Anxiety Rating Scale
Hamilton Depression Rating Scale
Massachusetts General Hospital Hairpulling (Skinpicking) Scale
Quality of Life Inventory
Sheehan Disability Scale
Skin Picking Symptom Assessment Scale
Tridimensional Personality Questionnaire
Week 6
NIMH Symptom Severity Scale (for TTM or Skin Picking)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Dermatillomania

Side Effects for

Stay
0%Psychiatric Hospitalization
0%Death
This histogram enumerates side effects from a completed 2009 Phase 4 trial (NCT00044655) in the Stay ARM group. Side effects include: Psychiatric Hospitalization with 0%, Death with 0%.

Trial Design

2 Treatment Groups

Aripiprazole
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Aripiprazole · Has Placebo Group · Phase 2

Aripiprazole
Drug
Experimental Group · 1 Intervention: Aripiprazole · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aripiprazole
2012
Completed Phase 4
~5520

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks

Trial Background

Prof. Jon E Grant, Professor
Principal Investigator
University of Chicago
Closest Location: University of Chicago · Chicago, IL
Photo of University of Chicago  1Photo of University of Chicago  2Photo of University of Chicago  3
2004First Recorded Clinical Trial
3 TrialsResearching Dermatillomania
705 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have current trichotillomania or skin picking disorder.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References